Association of Triglyceride-Glucose Index With Cognitive Function and Brain Atrophy: A Population-Based Study

Tian, Na; Song, Lin; Hou, Tingting; Fa, Wenxin; Dong, Yi; Liu, Rui; Ren, Yifei; Liu, Cuicui; Zhu, Min; Zhang, Heng; Wang, Yongxiang; Cong, Lin; Du, Yifeng; Qiu, Chengxuan

doi:10.1016/j.jagp.2023.09.007

Cited by 10 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association between brain volume, brain atrophy, and cognitive function has been extensively investigated in studies involving Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, and the general population; yet, few studies have explored the relationship between CI and white matter lesions, as well as brain atrophy, in CKD patients [ 28 , 35 , 36 , 37 , 38 ]. Yeh et al [ 39 ] found a significant correlation between attention and executive function and white matter lesions, but no correlation with brain atrophy.…”

Section: Relationship Between Brain Atrophy and CI In Ckd Patientsmentioning

confidence: 99%

Cognitive Impairment and Brain Atrophy in Patients with Chronic Kidney Disease

Tsuruya,

Yoshida

2024

JCM

View full text Add to dashboard Cite

In Japan, the aging of the population is rapidly accelerating, with an increase in patients with chronic kidney disease (CKD) and those undergoing dialysis. As a result, the number of individuals with cognitive impairment (CI) is rising, and addressing this issue has become an urgent problem. A notable feature of dementia in CKD patients is the high frequency of vascular dementia, making its prevention through the management of classical risk factors such as hypertension, diabetes mellitus, dyslipidemia, smoking, etc., associated with atherosclerosis and arteriosclerosis. Other effective measures, including the use of renin–angiotensin system inhibitors, addressing anemia, exercise therapy, and lifestyle improvements, have been reported. The incidence and progression of CI may also be influenced by the type of kidney replacement therapy, with reports suggesting that long-duration dialysis, low-temperature hemodialysis, peritoneal dialysis, and kidney transplantation can have a preferable effect on the preservation of cognitive function. In conclusion, patients with CKD are at a higher risk of developing CI, with brain atrophy being a contributing factor. Despite the identification of various preventive measures, the evidence substantiating their efficacy remains limited across all studies. Future expectations lie in large-scale randomized controlled trials.

show abstract

Section: Relationship Between Brain Atrophy and CI In Ckd Patientsmentioning

confidence: 99%

Cognitive Impairment and Brain Atrophy in Patients with Chronic Kidney Disease

Tsuruya,

Yoshida

2024

JCM

View full text Add to dashboard Cite

show abstract

Exploring the Association Between Cognitive Decline and Triglyceride‐Glucose Index: A Systematic Review and Meta‐Analysis

Ghondaghsaz,

Khalaji,

Mahalleh

et al. 2024

Brain and Behavior

View full text Add to dashboard Cite

BackgroundCognitive decline and dementia are debilitating conditions that compromise the quality of life and charge the healthcare system with a substantial socioeconomic burden. In this context, emerging evidence supports an association between the triglyceride‐glucose index (TyG), a surrogate insulin resistance marker, and cognitive decline and dementia. Hence, we systematically reviewed the studies assessing the TyG index in patients with cognitive decline and their controls.MethodsOnline international databases (PubMed, Scopus, Embase, and the Web of Science) were searched comprehensively for studies showing the TyG index in patients with cognitive decline/impairment. Random‐effect meta‐analyses were conducted to calculate the standardized mean difference (SMD), pooled odds ratio (OR), and pooled area under the curve (AUC), in addition to 95% confidence intervals (CIs) for the comparisons of groups.ResultsSeventeen studies were included in our analysis. Then, we conducted a meta‐analysis, demonstrating that patients with cognitive decline had significantly higher levels of TyG index than those without (SMD 0.83, 95% CI 0.16 to 1.50, p = 0.015). Moreover, our data showed that a 1‐unit increase in the TyG index was associated with higher odds of cognitive decline (adjusted OR [aOR] 2.86, 95% CI 1.49 to 5.50, p = 0.002). Further, we observed that patients in the fourth TyG quartile with higher values of the TyG index than the first quartile presented with more increased cognitive decline (aOR 1.62, 95%CI 1.11 to 2.38, p = 0.013). Finally, pooled AUC data for the diagnostic performance of the TyG index resulted in an overall AUC value of 0.73 (95% CI 0.66 to 0.79). Sensitivity and specificity were also calculated as 0.695 and 0.687, respectively.ConclusionThis study supports the clinical utility of the TyG index in patients with cognitive decline and solicits more focused studies to consolidate its usage in clinical settings and real‐world practice.

show abstract